冠脉搭桥与支架置入治疗冠心病多支病变的预后评价(3)
综上所述，对于冠心病复杂冠脉病变的治疗，尽管PCI的地位在不断地提高，CABG仍是不可替代的方式，且远期预后优于PCI。
参考文献：
[1]中华医学会心血管病学分会，中华心血管病杂志编辑委员会.中国心血管病预防指南[J].中华心血管病杂志，2011，39(1)：3-22.
[2]Levine GN，Bates ER，Blankenship JC，et al.2015 AHA ACC SCAI focused update on primary percutaneous coronary intervention for patients with ST elevation myocardial infarction[J].Circulation，2016，133： 1135-1147.
[3]付焕梅.心血管病危险因素与冠脉病变支数关系的分析[J].中国心血管病研究，2010，8(1)：36-39.
, 百拇医药
[4]Lee C W，Ahn J M，Cavalcante R，et al.Coronary Artery Bypass Surgery Versus Drug-Eluting Stent Implantation for Left Main or Multivessel Coronary Artery Disease：A Meta-Analysis of Individual Patient Data[J].Jacc Cardiovascular Interventions，2016：2481-2489.
[5]Fanari Z，Weiss S A，Zhang W，et al.Comparison of Percutaneous Coronary Intervention with Drug Eluting Stents Versus Coronary Artery Bypass Grafting in Patients With Multivessel Coronary Artery Disease：Meta-Analysis of Six Randomized Controlled Trials[J].Cardiovascular Revascularization Medicine，2015，15(1)：70-77.
, http://www.100md.com
[6]Mieres J，Herscovich N，Rodríguez A E.Coronary Stenting Remains the First Revascularization Option in Most Patients with a Clinical Indication for Myocardial Revascularization[M].Controversies in Cardiology. Springer International Publishing，2015：187-201.
[7]Serruys P，Religa G，Ruzyllo W，et al.TCT-42 Long-term Safety and Efficacy of Percutaneous Coronary Intervention With Stenting and Coronary Artery Bypass Surgery for Left Main Disease： Final Five-year Follow-up of the SYNTAX Trial[J].Journal of the American College of Cardiology，2012，60(17)：B13-B13.
, http://www.100md.com
[8]Alak A，Lugomirski P，Jolly S S.A Meta-Analysis of Randomized Controlled Trials of Everolimus-Eluting Stents Versus Bare-Metal Stents in Percutaneous Coronary Intervention[J].Canadian Journal of Cardiology，2013，29(10)：S337.
[9]Fajadet J，Wijns W，Laarman G J，et al.Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions： five year outcomes in the ENDEAVOR II study[J].Eurointervention Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology，2010，6(5)：562.
, http://www.100md.com
[10]Onuma Y，Wykrzykowska J，Vranckx P，et al.Multivessel coronary revascularization in patients with and without diabetes mellitus 5-year follow-up of the ARTS-II trial[J].Journal of the American College of Cardiology，2010，55(10)：A184.E1721-A184.E1721.
[11]Farooq V，van Klaveren D，Steyerberg EW，et al.Anatomical and clinical characteristic to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients：development and validation of SYNTAX score II[J].Lancet，2013， 381(9867)：639-650.
, http://www.100md.com
[12]Mohr FW，Morice MC，Kappetein AP，et al.Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease： 5-year follow-up of the randomised，clinical SYNTAX trial[J].Lancet，2013，381(9867)：629-638.
[13]中華医学会心血管病学分会介入心脏病学组，中国医师协会心血管内科医师分会血栓防治专业委员会，中华心血管病杂志编辑委员会.中国经皮冠状动脉介入治疗指南(2016)[J].中华心血管病杂志，2016，44(5)：382-400.编辑/成森, http://www.100md.com(曹静 孔祥 葛建军)
参考文献：
[1]中华医学会心血管病学分会，中华心血管病杂志编辑委员会.中国心血管病预防指南[J].中华心血管病杂志，2011，39(1)：3-22.
[2]Levine GN，Bates ER，Blankenship JC，et al.2015 AHA ACC SCAI focused update on primary percutaneous coronary intervention for patients with ST elevation myocardial infarction[J].Circulation，2016，133： 1135-1147.
[3]付焕梅.心血管病危险因素与冠脉病变支数关系的分析[J].中国心血管病研究，2010，8(1)：36-39.
, 百拇医药
[4]Lee C W，Ahn J M，Cavalcante R，et al.Coronary Artery Bypass Surgery Versus Drug-Eluting Stent Implantation for Left Main or Multivessel Coronary Artery Disease：A Meta-Analysis of Individual Patient Data[J].Jacc Cardiovascular Interventions，2016：2481-2489.
[5]Fanari Z，Weiss S A，Zhang W，et al.Comparison of Percutaneous Coronary Intervention with Drug Eluting Stents Versus Coronary Artery Bypass Grafting in Patients With Multivessel Coronary Artery Disease：Meta-Analysis of Six Randomized Controlled Trials[J].Cardiovascular Revascularization Medicine，2015，15(1)：70-77.
, http://www.100md.com
[6]Mieres J，Herscovich N，Rodríguez A E.Coronary Stenting Remains the First Revascularization Option in Most Patients with a Clinical Indication for Myocardial Revascularization[M].Controversies in Cardiology. Springer International Publishing，2015：187-201.
[7]Serruys P，Religa G，Ruzyllo W，et al.TCT-42 Long-term Safety and Efficacy of Percutaneous Coronary Intervention With Stenting and Coronary Artery Bypass Surgery for Left Main Disease： Final Five-year Follow-up of the SYNTAX Trial[J].Journal of the American College of Cardiology，2012，60(17)：B13-B13.
, http://www.100md.com
[8]Alak A，Lugomirski P，Jolly S S.A Meta-Analysis of Randomized Controlled Trials of Everolimus-Eluting Stents Versus Bare-Metal Stents in Percutaneous Coronary Intervention[J].Canadian Journal of Cardiology，2013，29(10)：S337.
[9]Fajadet J，Wijns W，Laarman G J，et al.Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions： five year outcomes in the ENDEAVOR II study[J].Eurointervention Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology，2010，6(5)：562.
, http://www.100md.com
[10]Onuma Y，Wykrzykowska J，Vranckx P，et al.Multivessel coronary revascularization in patients with and without diabetes mellitus 5-year follow-up of the ARTS-II trial[J].Journal of the American College of Cardiology，2010，55(10)：A184.E1721-A184.E1721.
[11]Farooq V，van Klaveren D，Steyerberg EW，et al.Anatomical and clinical characteristic to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients：development and validation of SYNTAX score II[J].Lancet，2013， 381(9867)：639-650.
, http://www.100md.com
[12]Mohr FW，Morice MC，Kappetein AP，et al.Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease： 5-year follow-up of the randomised，clinical SYNTAX trial[J].Lancet，2013，381(9867)：629-638.
[13]中華医学会心血管病学分会介入心脏病学组，中国医师协会心血管内科医师分会血栓防治专业委员会，中华心血管病杂志编辑委员会.中国经皮冠状动脉介入治疗指南(2016)[J].中华心血管病杂志，2016，44(5)：382-400.编辑/成森, http://www.100md.com(曹静 孔祥 葛建军)
参见：首页 > 医疗版 > 疾病专题 > 心血管科 > 冠状动脉病 > 冠心病